

Multiple myeloma: 2022 update on diagnosis, risk stratification, and management

S. Vincent Rajkumar 

Division of Hematology, Mayo Clinic,
Rochester, Minnesota, USA

Correspondence

S. Vincent Rajkumar, Division of Hematology,
Mayo Clinic, 200 First Street SW, Rochester,
MN 55905, USA.

Email: rajkumar.vincent@mayo.edu

Funding information

Marvin Family Grant; National Institutes of
Health, Grant/Award Numbers: CA 168762,
CA 186781

Abstract

Disease Overview: Multiple myeloma accounts for approximately 10% of hematologic malignancies.

Diagnosis: The diagnosis requires $\geq 10\%$ clonal bone marrow plasma cells or a biopsy-proven plasmacytoma *plus* evidence of one or more multiple myeloma defining events (MDE): CRAB (hypercalcemia, renal failure, anemia, or lytic bone lesions) attributable to the plasma cell disorder, bone marrow clonal plasmacytosis $\geq 60\%$, serum involved/uninvolved free light chain (FLC) ratio ≥ 100 (provided involved FLC is ≥ 100 mg/L), or >1 focal lesion on magnetic resonance imaging.

Risk Stratification: The presence of del(17p), t(4;14), t(14;16), t(14;20), gain 1q, or p53 mutation is considered high-risk multiple myeloma. The presence of any two high risk factors is considered double-hit myeloma, and three or more high risk factors is triple-hit myeloma.

Risk-Adapted Initial Therapy: In patients who are candidates for autologous stem cell transplantation, induction therapy consists of bortezomib, lenalidomide, dexamethasone (VRd) given for approximately 3–4 cycles followed by autologous stem cell transplantation (ASCT). In high-risk patients, daratumumab, bortezomib, lenalidomide, dexamethasone (Dara-VRd) is an alternative to VRd. Selected standard-risk patients can collect stem cells, get additional cycles of induction therapy, and delay transplant until first relapse. Patients who are not candidates for transplant are treated with VRd for approximately 8–12 cycles followed by maintenance or alternatively with daratumumab, lenalidomide, dexamethasone (DRd) until progression.

Maintenance Therapy: Standard-risk patients need lenalidomide maintenance, while bortezomib plus lenalidomide maintenance is needed for high-risk myeloma.

Management of Relapsed Disease: A triplet regimen is usually needed at relapse, with the choice of regimen varying with each successive relapse.

1 | DISEASE OVERVIEW

Multiple myeloma accounts for 1% of all cancers and approximately 10% of all hematologic malignancies.^{1,2} Each year, over 32 000 new cases are diagnosed in the United States, and almost 13 000 patients die of the disease.³ The annual *age-adjusted* incidence in the United States has remained stable for decades at approximately 4 per

100 000.⁴ Multiple myeloma is slightly more common in men than in women, and is twice as common in African Americans compared with Caucasians.⁵ The median age of patients at the time of diagnosis is about 65 years.⁶

Unlike other malignancies that metastasize to bone, the osteolytic bone lesions in multiple myeloma exhibit no new bone formation.⁷ Bone disease is the main cause of morbidity and can be

best detected using low-dose whole-body computed tomography (WB-CT), fluoro-deoxyglucose (FDG) positron emission tomography/computed tomographic scans (PET/CT), or magnetic resonance imaging (MRI).⁸ Other major clinical manifestations are anemia, hypercalcemia, renal failure, and an increased risk of infections. Approximately 1%–2% of patients have extramedullary disease (EMD) at the time of initial diagnosis, while 8% develop EMD later on in the disease course.⁹

Almost all patients with multiple myeloma evolve from an asymptomatic premalignant stage termed monoclonal gammopathy of undetermined significance (MGUS).^{10,11} MGUS is present in approximately 5% of the population above the age of 50,^{12–14} and the prevalence is approximately two-fold higher in Blacks compared with Whites.^{15,16} MGUS progresses to multiple myeloma or related malignancy at a rate of 1% per year.^{17,18} Since MGUS is asymptomatic, over 50% of individuals who are diagnosed with MGUS have had the condition for over 10 years prior to the clinical diagnosis.¹⁹ In some patients, an intermediate asymptomatic but more advanced premalignant stage referred to as smoldering multiple myeloma (SMM) can be recognized clinically.²⁰ SMM progresses to multiple myeloma at a rate of approximately 10% per year over the first 5 years following diagnosis, 3% per year over the next 5 years, and 1.5% per year thereafter. This rate of progression is influenced by the underlying cytogenetic type of disease: patients with t(4;14) translocation, del(17p), and gain (1q) are at a higher risk of progression from MGUS or SMM to multiple myeloma.^{21–23}

2 | DIAGNOSIS

The revised International Myeloma Working Group (IMWG) criteria for the diagnosis of multiple myeloma and related disorders are shown in Table 1.¹ The diagnosis of multiple myeloma requires the presence of one or more myeloma defining events (MDE) in addition to evidence of either 10% or more clonal plasma cells on bone marrow examination or a biopsy-proven plasmacytoma. MDE consists of established CRAB (hypercalcemia, renal failure, anemia, or lytic bone lesions) features as well as three specific biomarkers: clonal bone marrow plasma cells $\geq 60\%$, serum free light chain (FLC) ratio ≥ 100 (provided involved FLC level is ≥ 100 mg/L), and more than one focal lesion on MRI. Each of the new biomarkers is associated with an approximately 80% risk of progression to symptomatic end-organ damage in two or more independent studies. The updated criteria represent a paradigm shift since they allow early diagnosis and initiation of therapy before end-organ damage.

When multiple myeloma is suspected clinically, patients should be tested for the presence of M proteins using a combination of tests that should include a serum protein electrophoresis (SPEP), serum immunofixation (SIFE), and the serum FLC assay.²⁴ Approximately 2% of patients with multiple myeloma have true non-secretory disease and have no evidence of an M protein on any of the above studies.^{6,25} Bone marrow studies at the time of initial diagnosis should include fluorescent in situ hybridization (FISH)

probes designed to detect t(11;14), t(4;14), t(14;16), t(6;14), t(14;20), trisomies, and del(17p) (see risk stratification below).²⁶ Conventional karyotyping to detect hypodiploidy and deletion 13 has value, but if FISH studies are done, additional value in initial risk stratification is limited. Gene expression profiling (GEP) if available can provide additional prognostic value.²⁷ Serum CrossLaps to measure carboxy-terminal collagen crosslinks (CTX) may be useful in assessing bone turnover and to determine adequacy of bisphosphonate therapy.^{28,29} The extent of bone disease is best assessed by low-dose WB-CT or PET/CT imaging.^{8,30} MRI scans are useful in patients with suspected SMM to rule out focal bone marrow lesions that can be seen before true osteolytic disease occurs. MRI imaging is also useful in assessing extramedullary disease, suspected cord compression, or when detailed imaging of a specific symptomatic area is needed. Conventional skeletal survey is less sensitive than low-dose WB-CT and PET/CT and recommended only if resources for more advanced imaging are not available. The presence of $\geq 5\%$ circulating plasma cells in the conventional peripheral blood smear in patients otherwise diagnosed with multiple myeloma should be considered as plasma cell leukemia.³¹

The M protein is considered to be measurable if it is ≥ 1 gm/dL in the serum and or ≥ 200 mg/day in the urine. The M protein level is monitored by SPEP and serum FLC assay to assess treatment response every month while on therapy, and every 3–4 months when off-therapy. The serum FLC assay is particularly useful in patients who lack a measurable M protein, provided the FLC ratio is abnormal and the involved FLC level is ≥ 100 mg/L.³² Urine protein electrophoresis is recommended at least once every 3–6 months, to follow the urine M protein level as well as to detect other renal complications that may result in albuminuria. Response to therapy assessment and minimal residual disease (MRD) evaluation is based on the revised IMWG uniform response criteria.³³

3 | MOLECULAR CLASSIFICATION

Although multiple myeloma is still considered a single disease, it is in reality a collection of several different cytogenetically distinct plasma cell malignancies (Table 2).^{34,35} On FISH studies of the bone marrow, approximately 40% of multiple myeloma is characterized by the presence of trisomies in the neoplastic plasma cells (hyperdiploid multiple myeloma), while most of the rest have a translocation involving the immunoglobulin heavy chain (IgH) locus on chromosome 14q32 (IgH translocated multiple myeloma).^{36–39} A small proportion of patients have both trisomies and IgH translocations. Trisomies and IgH translocations are considered primary cytogenetic abnormalities and occur at the time of establishment of MGUS. In addition, other cytogenetic changes termed secondary cytogenetic abnormalities arise along the disease course of multiple myeloma, including gain(1q), del(1p), del(17p), del(13), and secondary translocations involving MYC. Both primary and secondary cytogenetic abnormalities can influence disease course, response to therapy, and prognosis. Importantly, the interpretation

TABLE 1 International Myeloma Working Group Diagnostic Criteria for multiple myeloma and related plasma cell disorders

Disorder	Disease definition
Non-IgM monoclonal gammopathy of undetermined significance (MGUS)	All three criteria must be met: <ul style="list-style-type: none"> • Serum monoclonal protein (non-IgM type) <3 gm/dL • Clonal bone marrow plasma cells <10%^a • Absence of end-organ damage such as hypercalcemia, renal insufficiency, anemia, and bone lesions (CRAB) that can be attributed to the plasma cell proliferative disorder
Smoldering multiple myeloma	Both criteria must be met: <ul style="list-style-type: none"> • Serum monoclonal protein (IgG or IgA) ≥3 gm/dL, or urinary monoclonal protein ≥500 mg per 24 h and/or clonal bone marrow plasma cells 10%–60% • Absence of myeloma defining events or amyloidosis
Multiple Myeloma	Both criteria must be met: <ul style="list-style-type: none"> • Clonal bone marrow plasma cells ≥10% or biopsy-proven bony or extramedullary plasmacytoma • Any one or more of the following myeloma defining events: <ul style="list-style-type: none"> ◦ Evidence of end-organ damage that can be attributed to the underlying plasma cell proliferative disorder, specifically: <ul style="list-style-type: none"> • Hypercalcemia: serum calcium >0.25 mmol/L (>1 mg/dL) higher than the upper limit of normal or >2.75 mmol/L (>11 mg/dL) • Renal insufficiency: creatinine clearance <40 mL per minute or serum creatinine >177 μmol/L (>2 mg/dL) • Anemia: hemoglobin value of >2 g/dL below the lower limit of normal, or a hemoglobin value <10 g/dL • Bone lesions: one or more osteolytic lesions on skeletal radiography, computed tomography (CT), or positron emission tomography-CT (PET-CT) ◦ Clonal bone marrow plasma cell percentage ≥ 60% ◦ Involved: uninvolved serum free light chain (FLC) ratio ≥ 100 (involved free light chain level must be ≥100 mg/L) ◦ >1 focal lesions on magnetic resonance imaging (MRI) studies (at least 5 mm in size)
Plasma cell leukemia	Both criteria must be met: <ul style="list-style-type: none"> • Meets diagnostic criteria for multiple myeloma • Presence of 5% or more plasma cells in conventional peripheral blood smear white blood cell differential count
IgM monoclonal gammopathy of undetermined significance (IgM MGUS)	All three criteria must be met: <ul style="list-style-type: none"> • Serum IgM monoclonal protein <3 gm/dL • Bone marrow lymphoplasmacytic infiltration <10% • No evidence of anemia, constitutional symptoms, hyperviscosity, lymphadenopathy, or hepatosplenomegaly that can be attributed to the underlying lymphoproliferative disorder.
Light chain MGUS	All criteria must be met: <ul style="list-style-type: none"> • Abnormal FLC ratio (<0.26 or >1.65) • Increased level of the appropriate involved light chain (increased kappa FLC in patients with ratio >1.65 and increased lambda FLC in patients with ratio <0.26) • No immunoglobulin heavy chain expression on immunofixation • Absence of end-organ damage that can be attributed to the plasma cell proliferative disorder • Clonal bone marrow plasma cells <10% • Urinary monoclonal protein <500 mg/24 h
Solitary plasmacytoma	All four criteria must be met <ul style="list-style-type: none"> • Biopsy-proven solitary lesion of bone or soft tissue with evidence of clonal plasma cells • Normal bone marrow with no evidence of clonal plasma cells • Normal skeletal survey and MRI (or CT) of spine and pelvis (except for the primary solitary lesion) • Absence of end-organ damage such as hypercalcemia, renal insufficiency, anemia, or bone lesions (CRAB) that can be attributed to a lympho-plasma cell proliferative disorder
Solitary plasmacytoma with minimal marrow involvement ^b	All four criteria must be met <ul style="list-style-type: none"> • Biopsy-proven solitary lesion of bone or soft tissue with evidence of clonal plasma cells • Clonal bone marrow plasma cells <10% • Normal skeletal survey and MRI (or CT) of spine and pelvis (except for the primary solitary lesion) • Absence of end-organ damage such as hypercalcemia, renal insufficiency, anemia, or bone lesions (CRAB) that can be attributed to a lympho-plasma cell proliferative disorder

Note: Reproduced from Reference 1.

^aA bone marrow can be deferred in patients with low-risk MGUS (IgG type, M protein <15 gm/L, normal free light chain ratio) in whom there are no clinical features concerning myeloma.

^bSolitary plasmacytoma with 10% or more clonal plasma cells is considered as multiple myeloma.

and impact of cytogenetic abnormalities in multiple myeloma vary depending on the disease phase in which they are detected (Table 3).⁴⁰ Studies show that myeloma is associated with more than 400 canonical somatic mutations per patient, and the most commonly mutated genes include immunoglobulin heavy chain and light chain genes, *NRAS*, *KRAS*, and *BRAF*.⁴¹

4 | PROGNOSIS AND RISK STRATIFICATION

Survival estimates in multiple myeloma vary based on the source of the data. Data from randomized controlled trials using modern therapy show that the median survival in multiple myeloma is approximately 6 years.⁴² In the subset of patients eligible for ASCT, 4-year survival rates are more than 80%;⁴³ the median overall survival (OS) among these patients is more than 8 years.^{44,45} Among elderly patients (age > 75 years), median OS is lower, and is approximately 5 years.^{42,46} These numbers likely underestimate current survival probabilities since they predate the arrival of monoclonal antibodies and several other new agents that have been introduced in the last 5 years. On the other hand, they may be overestimates of the true population-based survival since they are derived from randomized controlled trials where patients with poor performance status and comorbidities are typically excluded. Nevertheless, these estimates are valuable benchmarks, and appear generalizable to newly diagnosed myeloma patients in good performance status.⁴⁷

More precise estimation of prognosis requires an assessment of multiple factors. As in other cancers, OS in multiple myeloma is affected by host characteristics, tumor burden (stage), biology (cytogenetic abnormalities), and response to therapy.^{48,49} Tumor burden in multiple myeloma has traditionally been assessed using the Durie–Salmon staging (DSS)⁵⁰ and the International Staging System (ISS).^{51,52} Disease biology is best reflected based on the molecular subtype of multiple myeloma (Table 2), the presence or absence of secondary cytogenetic abnormalities such as del(17p), gain(1q), or del(1p).^{26,53} In addition to cytogenetic risk factors, two other markers that are associated with aggressive disease biology are elevated serum lactate dehydrogenase and evidence of circulating plasma cells on routine peripheral smear examination (plasma cell leukemia). The Revised International Staging System (RISS) combines elements of tumor burden (ISS) and disease biology (presence of high-risk cytogenetic abnormalities or elevated lactate dehydrogenase level) to create a unified prognostic index that helps in clinical care as well as in comparison of clinical trial data (Table 4).⁵⁴ In order to ensure uniform availability, only three widely available cytogenetic markers are used in the RISS; the Mayo Clinic mSMART risk stratification (www.msmart.org) (Table 5) has additional detail that is valuable in formulating a therapeutic strategy.

Treated appropriately, the survival of patients with certain high-risk categories can approach that of patients with standard-risk

TABLE 2 Primary molecular cytogenetic classification of multiple myeloma

Subtype	Gene(s)/chromosomes affected	Approximate percentage of myeloma patients
Hyperdiploid multiple myeloma ^a	Recurrent trisomies involving odd-numbered chromosomes with the exception of chromosomes 1, 13, and 21	45
IgH translocated multiple myeloma		40
t(11;14) (q13;q32)	<i>CCND1</i> (cyclin D1)	20
t(6;14) (p21;q32)	<i>CCND3</i> (cyclin D3)	5
t(4;14) (p16;q32)	<i>NSD2</i>	10
t(14;16) (q32;q23)	<i>C-MAF</i>	4
t(14;20) (q32;q11)	<i>MAFB</i>	<1
Other IgH translocations, other cytogenetic abnormalities, or normal		5

Note: Modified from Reference 53.

^aRequires absence of an immunoglobulin heavy chain translocation. If an immunoglobulin heavy chain translocation is present, classification will be based on that abnormality.

disease. In a large trial using bortezomib-based induction, early ASCT, and bortezomib maintenance, the median OS of patients with del(17p) was approximately 8 years (8-year survival rate of 52%), and was identical to patients with standard-risk multiple myeloma. In contrast, survival was lower for patients with t(4;14) translocation (8-year survival rate, 33%) and for patients with gain (1q) abnormality (8-year survival rate, 36%).⁴⁴ These findings underscore the limitations of current risk stratification models in the context of modern therapy and highlight the need to stratify multiple myeloma based on individual cytogenetic groups rather than arbitrary heterogeneous risk categories.³⁴

5 | TREATMENT OF NEWLY DIAGNOSED MYELOMA

Survival in multiple myeloma has improved significantly in the last 15 years.⁵⁵ The initial impact came from the introduction of thalidomide,⁵⁶ bortezomib,⁵⁷ and lenalidomide.^{58,59} In the last decade, carfilzomib, pomalidomide, ixazomib, elotuzumab, daratumumab, isatuximab, selinexor, belantamab mafodotin, and chimeric antigen receptor-T (CAR-T) cell therapies have been approved by the Food and Drug Administration (FDA) for the treatment of relapsed multiple myeloma, and promise to improve outcomes further. Numerous combinations have been developed using drugs that have shown activity in multiple myeloma, and the most commonly used regimens are listed

TABLE 3 Cytogenetic abnormalities on clinical course and prognosis in multiple myeloma

Cytogenetic abnormality	Clinical setting in which abnormality is detected	
	Smoldering multiple myeloma	Multiple myeloma
Trisomies	Intermediate risk of progression, median TTP of 3 years	Good prognosis, standard-risk MM, median OS 7–10 years Most have myeloma bone disease at diagnosis Excellent response to lenalidomide-based therapy
t(11;14) (q13;q32)	Standard risk of progression, median TTP of 5 years	Good prognosis, standard-risk MM, median OS 7–10 years
t(6;14) (p21;q32)	Standard risk of progression, median TTP of 5 years	Good prognosis, standard-risk MM, median OS 7–10 years
t(4;14) (p16;q32)	High risk of progression, median TTP of 2 years	Intermediate-risk MM, median OS 5 years Needs bortezomib-based initial therapy, early ASCT (if eligible), followed by bortezomib-based consolidation/maintenance
t(14;16) (q32;q23)	Standard risk of progression, median TTP of 5 years	High-risk MM, median OS 3 years Associated with high levels of FLC and 25% present with acute renal failure as initial MDE
t(14;20) (q32;q11)	Standard risk of progression, median TTP of 5 years	High-risk MM, median OS 3 years
Gain(1q21)	High risk of progression, median TTP of 2 years	Intermediate-risk MM, median OS 5 years
Del(17p)	High risk of progression, median TTP of 2 years	High-risk MM, median OS 3 years
Trisomies plus any one of the IgH translocations	Standard risk of progression, median TTP of 5 years	May ameliorate adverse prognosis conferred by high-risk IgH translocations, and del 17p
Isolated Monosomy 13, or Isolated Monosomy 14	Standard risk of progression, median TTP of 5 years	Effect on prognosis is not clear
Normal	Low risk of progression, median TTP of 7–10 years	Good prognosis, probably reflecting low tumor burden, median OS >7–10 years

Note: Reproduced from Reference 40.

Abbreviations: ASCT, autologous stem cell transplantation; FISH, fluorescent in situ hybridization; MM, multiple myeloma; OS, overall survival; SMM, Smoldering multiple myeloma; TTP, time to progression.

in Table 6.^{60–74} These drugs work through a variety of mechanisms, some of which are not fully understood. Thalidomide, lenalidomide, and pomalidomide are termed immunomodulatory agents (IMiDs). IMiDs bind to cereblon and activate cereblon E3 ligase activity, resulting in the rapid ubiquitination and degradation of two specific B cell transcription factors, Ikaros family zinc finger proteins Ikaros (IKZF 1) and Aiolos (IKZF3).^{75–77} They may cause direct cytotoxicity by inducing free radical mediated DNA damage.⁷⁸ They also have anti-angiogenic, immunomodulatory, and tumor necrosis factor alpha inhibitory properties. Bortezomib, carfilzomib, and ixazomib are proteasome inhibitors.^{79–81} Elotuzumab targets SLAMF7; daratumumab and isatuximab target CD38 respectively.^{82–85} Belantamab mafodotin is a humanized antibody targeting B cell maturation agent (BCMA) that is conjugated to monomethyl auristatin-F, a microtubule disrupting agent.⁸⁶ Idecabtagene vicleucel (ide-cel, bb2121)

and ciltacabtagene autoleucel (cilta-cel) are newly approved CAR-T products targeting BCMA that are active in relapsed refractory myeloma.

The approach to treatment of symptomatic newly diagnosed multiple myeloma is outlined in Figure 1 and is dictated by eligibility for ASCT and risk stratification. The data to support their use from recent randomized trials using new active agents for multiple myeloma are provided in Table 7.^{42,43,87–90} In order to initiate therapy, patients must meet the criteria for multiple myeloma as outlined in Table 1. Early therapy with lenalidomide and dexamethasone or single-agent lenalidomide is beneficial in patients with high-risk SMM, and is discussed separately.^{91,92}

There is an ongoing “cure versus control” debate on whether we should treat multiple myeloma with an aggressive multi-drug strategy targeting complete response (CR) or a sequential disease control

TABLE 4 Revised international staging system for myeloma⁵⁴

Stage
Stage 1 All of the following: <ul style="list-style-type: none"> • Serum albumin ≥ 3.5 gm/dL • Serum beta-2-microglobulin < 3.5 mg/L • No high-risk cytogenetics • Normal serum lactate dehydrogenase level
Stage II <ul style="list-style-type: none"> • Not fitting Stage I or III
Stage III Both of the following: <ul style="list-style-type: none"> • Serum beta-2-microglobulin > 5.5 mg/L • High-risk cytogenetics [t(4;14), t(14;16), or del(17p)] or Elevated serum lactate dehydrogenase level

Note: Derived from Reference 54.

approach that emphasizes quality of life as well as OS.^{93,94} Recent data show that MRD negative status (as estimated by next-generation molecular methods or flow cytometry) has favorable prognostic value.³³ However, additional trials are needed to determine if changes in treatment need to be made based on MRD status. At present, MRD results are recommended mainly as a prognostic metric and not for making treatment decisions. We also need additional data to determine if MRD negativity can be used as a surrogate endpoint for regulatory approval, and if sustained MRD negativity may be a marker of cure in at least a subset of patients.³⁵

5.1 | Initial treatment in patients eligible for ASCT

Typically, patients are treated with approximately 3–4 cycles of induction therapy prior to stem cell harvest. After harvest, patients can either undergo frontline ASCT or resume induction therapy delaying ASCT until first relapse. There are many options for initial therapy, and the most common treatment regimens are discussed below. These regimens can also be used at the time of relapse. In general, the low-dose dexamethasone regimen (40 mg once a week) is preferred in all regimens to minimize toxicity. In a randomized trial conducted by the Eastern Cooperative Oncology Group (ECOG), the low-dose dexamethasone approach was associated with superior OS and significantly lower toxicity.⁹⁵

5.1.1 | Triplet regimens

Bortezomib, lenalidomide, dexamethasone (VRd) and daratumumab, lenalidomide, dexamethasone (DRd) are the current standard of care options for newly diagnosed multiple myeloma.^{42,87} In a randomized trial conducted by the Southwest Oncology Group (SWOG), response rates, PFS, and OS were significantly superior with VRd compared with Rd (Table 7).⁴² Stem cell collection with granulocyte stimulating factor (G-CSF) alone may

TABLE 5 Mayo clinic risk stratification for multiple myeloma (mSMART)

Risk group	Percentage of newly diagnosed patients with the abnormality
Standard risk	60%
Trisomies	
t(11;14)	
t(6;14)	
High risk	40%
t(4;14)	
t(14;16)	
t(14;20)	
del(17p)	
gain(1q)	
Double-Hit myeloma: Any two high-risk factors	
Triple-Hit myeloma: Any three or more high-risk factors	

be impaired when lenalidomide is used as induction therapy.⁹⁶ Patients who have received more than 4–6 cycles of lenalidomide may need plerixafor for stem cell mobilization. All patients treated with lenalidomide require anti-thrombosis prophylaxis. Aspirin is adequate for most patients, but in patients who are at higher risk of thrombosis, prophylactic anticoagulation with low-molecular weight heparin, warfarin, or a direct-acting oral anticoagulant such as apixaban and rivaroxaban is needed.^{97–99} Daratumumab, lenalidomide, dexamethasone (DRd) has shown significant activity in patients who are not candidates for transplantation, and is a reasonable alternative to VRd from frontline therapy.⁸⁷ If lenalidomide is not available for use as initial therapy or in the presence of acute renal failure, other bortezomib-containing regimens such as bortezomib–thalidomide–dexamethasone (VTd) or bortezomib–cyclophosphamide–dexamethasone (VCd) can be used instead of VRd. A recent randomized trial found that VTd results in superior response rates compared with VCd, but the impact on long-term outcomes is not known.¹⁰⁰ Therefore, both are reasonable alternatives to VRd and DRd.

In initial studies, peripheral neuropathy was a major concern with bortezomib therapy. Neuropathy with bortezomib can occur abruptly, and can be significantly painful and debilitating. However, the neurotoxicity of bortezomib can be greatly diminished by administering bortezomib once a week instead of twice weekly,^{101,102} and by administering the drug subcutaneously instead of the intravenous route.¹⁰³ The once-weekly subcutaneous bortezomib schedule (Table 6) has made serious neuropathy an uncommon problem, and has made regimens such as VRd, VCd, and VTd much more tolerable. Bortezomib does not appear to have any adverse effect on stem cell mobilization.¹⁰⁴

Two phase II trials reported results with carfilzomib when used in combination with lenalidomide and dexamethasone for newly

TABLE 6 Major treatment regimens in multiple myeloma

Regimen	Usual dosing schedule ^a
Bortezomib–Thalidomide–Dexamethasone (VTd) ^{b60}	Bortezomib 1.3 mg/m ² subcutaneous Days 1, 8, 15, 22 Thalidomide 100–200 mg oral Days 1–21 Dexamethasone 20 mg oral on day of and day after bortezomib (or 40 mg Days 1, 8, 15, 22) Repeated every 4 weeks × 4 cycles as pre-transplant induction therapy
Bortezomib–Cyclophosphamide–Dexamethasone ^b (VCd or CyBord) ^{61,62}	Cyclophosphamide 300 mg/m ² orally on Days 1, 8, 15 and 22 Bortezomib 1.3 mg/m ² subcutaneous on Days 1, 8, 15, 22 Dexamethasone 40 mg oral on days on Days 1, 8, 15, 22 Repeated every 4 weeks ^c
Bortezomib–Lenalidomide–Dexamethasone (VRd) ^{b62,63}	Bortezomib 1.3 mg/m ² subcutaneous Days 1, 8, 15 Lenalidomide 25 mg oral Days 1–14 Dexamethasone 20 mg oral on day of and day after bortezomib (or 40 mg Days 1, 8, 15, 22) Repeated every 3 weeks ^d
Carfilzomib–Cyclophosphamide–Dexamethasone (KCd) ^{e64}	Carfilzomib 20 mg/m ² (days 1 and 2 of Cycle 1) and 27 mg/m ² (subsequent doses) intravenously on Days 1, 2, 8, 9, 15, 16 Cyclophosphamide 300 mg/m ² orally on Days 1, 8, 15 Dexamethasone 40 mg oral on days on Days 1, 8, 15, 22 Repeated every 4 weeks
Carfilzomib–Lenalidomide–Dexamethasone (KRd) ^{e65}	Carfilzomib 20 mg/m ² (days 1 and 2 of Cycle 1) and 27 mg/m ² (subsequent doses) intravenously on Days 1, 2, 8, 9, 15, 16 Lenalidomide 25 mg oral Days 1–21 Dexamethasone 40 mg oral Days 1, 8, 15, 22 Repeated every 4 weeks
Carfilzomib–Pomalidomide–Dexamethasone (KPd) ^{e66}	Carfilzomib 20 mg/m ² (days 1 and 2 of Cycle 1) and 27 mg/m ² (subsequent cycles) intravenously on Days 1, 2, 8, 9, 15, 16 Pomalidomide 4 mg oral on Days 1–21 Dexamethasone 40 mg oral on days on Days 1, 8, 15, 22 Repeated every 4 weeks
Daratumumab–Lenalidomide–Dexamethasone (DRd) ⁶⁷	Daratumumab 16 mg/kg intravenously weekly × 8 weeks, and then every 2 weeks for 4 months, and then once monthly Lenalidomide 25 mg oral Days 1–21 Dexamethasone 40 mg intravenous Days 1, 8, 15, 22 (given oral on days when no daratumumab is being administered) Lenalidomide–Dexamethasone repeated in usual schedule every 4 weeks
Daratumumab–Bortezomib–Dexamethasone (DVd) ^{b68}	Daratumumab 16 mg/kg intravenously weekly × 8 weeks, and then every 2 weeks for 4 months, and then once monthly Bortezomib 1.3 mg/m ² subcutaneous on Days 1, 8, 15, 22 Dexamethasone 40 mg intravenous Days 1, 8, 15, 22 (given oral on days when no daratumumab is being administered) Bortezomib–Dexamethasone repeated in usual schedule every 4 weeks
Daratumumab–Pomalidomide–Dexamethasone (DPd) ⁶⁹	Daratumumab 16 mg/kg intravenously weekly × 8 weeks, and then every 2 weeks for 4 months, and then once monthly Pomalidomide 4 mg oral on Days 1–21 Dexamethasone 40 mg intravenous Days 1, 8, 15, 22 (given oral on days when no daratumumab is being administered) Repeated every 4 weeks
Daratumumab–Carfilzomib–Dexamethasone (DKd) ^{b70}	Daratumumab 1800 mg subcutaneously (or 16 mg/kg intravenously) weekly × 8 weeks, and then every 2 weeks for 4 months, and then once monthly Carfilzomib 56–70 mg/m ² Days 1, 8, and 15 (Cycle 1, Day 1 dose is 20 mg/m ²) Dexamethasone 40 mg Days 1, 8, 15, 22 Carfilzomib–Dexamethasone repeated in usual schedule every 4 weeks

(Continues)

TABLE 6 (Continued)

Regimen	Usual dosing schedule ^a
Ixazomib–Lenalidomide–Dexamethasone (IRd) ⁷¹	Ixazomib 4 mg oral Days 1, 8, 15 Lenalidomide 25 mg oral Days 1–21 Dexamethasone 40 mg oral Days 1, 8, 15, 22 Repeated every 4 weeks
Elotuzumab–Pomalidomide–Dexamethasone (EPd) ⁷²	Elotuzumab 10 mg/kg intravenously weekly × 8 weeks, and then 20 mg/kg every 4 weeks Pomalidomide 4 mg oral Days 1–21 Dexamethasone per prescribing information Lenalidomide–Dexamethasone repeated in usual schedule every 4 weeks
Isatuximab–Pomalidomide–Dexamethasone (Isa-Pd) ⁷³	Isatuximab 10 mg/kg intravenously weekly × 4 weeks, and then every 2 weeks Pomalidomide 4 mg oral Days 1–21 Dexamethasone per prescribing information Pomalidomide–Dexamethasone repeated in usual schedule every 4 weeks
Isatuximab–Carfilzomib–Dexamethasone (Isa-Kd) ^{b74}	Isatuximab 10 mg/kg intravenously weekly × 4 weeks, and then every 2 weeks Carfilzomib 56–70 mg/m ² Days 1, 8, and 15 (Cycle 1, Day 1 dose is 20 mg/m ²) Dexamethasone 40 mg Days 1, 8, 15, 22 Carfilzomib–Dexamethasone repeated in usual schedule every 4 weeks

^aAll doses need to be adjusted for performance status, renal function, blood counts, and other toxicities.

^bDoses of dexamethasone and/or bortezomib/carfilzomib reduced based on other data showing lower toxicity and similar efficacy with reduced doses; dose of selinexor reduced based on better tolerability with once-weekly dosing in subsequent randomized trial; subcutaneous route of administration of bortezomib preferred based on data showing lower toxicity and similar efficacy compared with intravenous administration.

^cThe Day 22 dose of all three drugs is omitted if counts are low, or after initial response to improve tolerability, or when the regimen is used as maintenance therapy; When used as maintenance therapy for high-risk patients, further delays can be instituted between cycles.

^dOmit Day 15 dose if counts are low or when the regimen is used as maintenance therapy; When used as maintenance therapy for high-risk patients, lenalidomide dose may be decreased to 10–15 mg per day, and delays can be instituted between cycles as done in total therapy protocols.

^eCarfilzomib can also be considered in a once a week schedule of 56–70 mg/m² on Days 1, 8, and 15 every 28 days (Cycle 1, Day 1 should be 20 mg/m²); Day 8, 9 doses of carfilzomib can be omitted in maintenance phase of therapy after a good response to improve tolerability; KcD dosing lowered from that used in the initial trial which was conducted in newly diagnosed patients.

diagnosed multiple myeloma.^{105,106} However, there is a concern for greater risk of serious toxicity with carfilzomib, and more data are needed. Further, a randomized trial in the United States (referred to as the ENDURANCE trial) found no benefit of carfilzomib, lenalidomide, dexamethasone (KRd) over VRd in standard-risk patients with newly diagnosed myeloma.⁹⁰

5.1.2 | Quadruplet regimens


Quadruplet regimens containing daratumumab, a monoclonal antibody targeting CD38, are showing promise. In one randomized trial, daratumumab, bortezomib, thalidomide, dexamethasone (Dara-VTd) showed superior response rates, PFS, and a trend to better OS compared with VTd.⁸⁸ A randomized phase II trial has found that daratumumab plus VRd (Dara-VRd) increases the rate and depth of response to therapy and prolongs PFS compared with VRd.¹⁰⁷ In these trials, as expected, the benefit of daratumumab in terms of surrogate endpoints was more pronounced in the standard-risk patients: a positive effect was nevertheless seen in both standard and high-risk disease. Phase III data on the incremental OS benefit

with quadruplet regimens over the current standard of VRd are awaited. At this point, it is prudent to restrict the use of quadruplet regimens to transplant eligible patients with high-risk double- or triple-hit myeloma, until we have clear OS data to justify adding potential long-term costs and risks to standard-risk patients who currently have excellent outcomes with the VRd triplet. Trials with other quadruplet regimens are ongoing. A randomized trial called the EQUATE trial to determine the patient subset that can benefit most from quadruplets is now enrolling in the United States (NCT04566328).

5.1.3 | Multidrug combinations

Besides the regimens discussed above, other options include anthracycline-containing regimens such as bortezomib, doxorubicin, dexamethasone (PAD)⁴⁴ or multi-agent combination chemotherapy regimens such as VDT-PACE (bortezomib, dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, and etoposide).^{108,109} These regimens are particularly useful in patients with aggressive disease such as plasma cell leukemia or multiple extramedullary

FIGURE 1 Approach to the treatment of newly diagnosed multiple myeloma in transplant eligible (A) and transplant-ineligible (B) patients. ASCT, autologous stem cell transplantation; Dara-VRd, daratumumab, bortezomib, lenalidomide, dexamethasone; DRd, daratumumab, lenalidomide, dexamethasone; VRd, bortezomib, lenalidomide, dexamethasone.



plasmacytomas. Several other regimens have been tested in newly diagnosed multiple myeloma, but there are no clear data from randomized controlled trials that they have an effect on long-term endpoints compared with the regimens discussed earlier.

Recommendations

- In standard-risk patients eligible for ASCT, I favor VRd as initial therapy for 3–4 cycles, followed by ASCT and lenalidomide maintenance therapy. In patients who are tolerating therapy and responding well, an alternative is VRd for 8–12 cycles followed by lenalidomide maintenance therapy; in such patients stem cells must be collected for cryopreservation after the first 3–4 cycles of VRd, and ASCT must be considered at first relapse.
- In high-risk patients, especially those with double-hit or triple-hit myeloma, I favor Dara-VRd as initial therapy for 3–4 cycles followed by ASCT and then maintenance with bortezomib plus lenalidomide.
- In patients with significant pre-existing or treatment-emergent neuropathy, DRd (standard-risk) and KRd (high-risk) are alternatives to VRd.
- In patients presenting with acute renal failure suspected to be secondary to light-chain cast nephropathy, I prefer Vcd or daratumumab plus Vcd as initial therapy in conjunction with plasma exchange (or dialysis with high cutoff filter). Plasma exchange is continued daily until the serum free light chain

levels are less than 50 mg/dL and then repeated as needed till chemotherapy is fully effective.

- In patients presenting with plasma cell leukemia or multiple extramedullary plasmacytomas, I prefer VDT-PACE as initial therapy followed by ASCT and then maintenance with a bortezomib-based regimen.
- Once-weekly subcutaneous bortezomib is preferred in most patients for initial therapy, unless there is an urgent need for rapid disease control.
- Dexamethasone 40 mg once a week (low-dose dexamethasone) is preferred in most patients for initial therapy, unless there is felt to be an urgent need for rapid disease control.

5.2 | Initial treatment in patients not eligible for ASCT

In patients with newly diagnosed multiple myeloma who are not candidates for ASCT due to age or other comorbidities, the major options for initial therapy are VRd and DRd, similar to patients who are candidates for ASCT. Although melphalan-based regimens have been extensively tested in these patients, they are not recommended due to concerns about stem cell damage and secondary myelodysplastic syndrome and leukemia. In the United States, transplant eligibility is not determined by a strict age cutoff, and many patients enrolled in the melphalan-based clinical trials would be considered candidates for ASCT.

TABLE 7 Results of recent phase III randomized studies in newly diagnosed myeloma

Trial	Regimen	No. of patients	Overall response rate (%)	CR plus VGPR (%)	Progression-free survival (Median in months)	p value for progression-free survival	Overall survival (Median in months) ^a	p value for overall survival
Durie et al. (S0777) ⁴²	Rd	229	72	32	31	.002	64	.025
	VRd	242	82	43	43		75	
Attal et al. (IFM 2009) ⁴³	VRd	350	97	77	36	<.001	NR; 82% at 4 years	.87
	VRd-ASCT	350	98	88	50		NR; 81% at 4 years	
Facon et al. (MAIA) ⁸⁷	Rd	369	81	53	32	<.001	NR	N/A
	DRd	368	93	79	NR; 71% at 30 months		NR	
Moreau et al. (CASSIOPEIA) ⁸⁸	VTd	542	90	78	NR; 85% at 18 months	<.001	NR; 90% at 30 months	p < .05
	Dara-VTd	543	90	83	NR; 93% at 18 months		NR; 96% at 30 months	
Facon et al. (TOURMALINE MM2) ⁸⁹	Rd	354	80	48	22	.073	NR; 52% at 5 years	.99
	IRd	351	82	63	35		NR; 52% at 5 years	
Kumar et al. (ENDURANCE) ⁹⁰	VRd	542	85	65	34	.74	84 at 3 years	.92
	KRd	545	87	74	35		86 at 3 years	

Abbreviations: ASCT, autologous stem cell transplantation; CR, complete response; Dara-VTd, daratumumab, bortezomib, thalidomide, dexamethasone; DRd, daratumumab, lenalidomide, dexamethasone; IRd, ixazomib, lenalidomide, dexamethasone; KRd, carfilzomib, lenalidomide, dexamethasone; N/A, not available; Rd, lenalidomide plus dexamethasone; VGPR, very good partial response; VRd, bortezomib, lenalidomide plus dexamethasone; VTd, bortezomib, thalidomide, dexamethasone.

^aEstimated from survival curves when not reported.

5.2.1 | Bortezomib-based regimens

VRd has shown a survival benefit compared with Rd, and is the preferred choice for initial therapy in patients who are not candidates for ASCT (Table 7).⁴² VRd is administered for approximately 8–12 cycles, followed by maintenance therapy. In patients in whom initial therapy with VRd is not possible mainly for logistical reasons (such as problems with compliance due to need for parenteral administration), ixazomib can be considered in place of bortezomib.⁸⁹ In frail elderly patients, a lower dose of lenalidomide should be used; dexamethasone may be started at 20 mg once a week, then reduced as much as possible after the first 4–6 cycles, and discontinued after the first year.

5.2.2 | Daratumumab, lenalidomide, dexamethasone (DRd)

DRd has been recently approved for patients with newly diagnosed myeloma, based on the results of an international multicenter randomized trial.⁸⁷ PFS at 30 months was higher with DRd compared with Rd, 70.6% versus 55.6%, $p < .001$. MRD negative rates were also superior, 24.2% versus 7.3%, $p < .001$. DRd is an alternative to VRd in this setting. However, unlike VRd where the triplet regimen is only

used for a limited duration, therapy with DRd requires treatment with all three drugs until progression, which makes this a much more expensive regimen in the long term.¹¹⁰

5.2.3 | Alkylator-based regimens

Melphalan-based regimens are considered only if there are problems with access to lenalidomide. Even in these situations, the risks of melphalan can be reduced by using cyclophosphamide instead, and studies show this substitution does not alter efficacy.¹¹¹ Thus, the VCd regimen can be considered as a minor modification of the VMP regimen, in which cyclophosphamide is used as the alkylating agent in place of melphalan. This variation has the advantage of not affecting stem cell mobilization, and dosing is more predictable. A randomized trial found superior PFS and OS with a four-drug regimen of Dara plus VMP compared with VMP in a randomized phase III trial, but the contribution of the fourth drug to the induction component cannot be ascertained from this trial.¹¹²

Recommendations

- In standard-risk patients, I prefer VRd as initial therapy administered for approximately 8–12 cycles, followed by lenalidomide

maintenance. DRd is an alternative to VRd but adds cost and toxicity to long-term triplet therapy.

- In high-risk patients, I favor VRd as initial therapy for approximately 8–12 cycles followed by bortezomib plus lenalidomide maintenance.

5.3 | Hematopoietic stem cell transplantation

5.3.1 | Autologous stem cell transplantation (ASCT)

ASCT improves median OS in multiple myeloma by approximately 12 months.^{113–116} However, randomized trials found similar OS with early ASCT (immediately following 4 cycles of induction therapy) versus delayed ASCT (at the time of relapse as salvage therapy).^{117–119} A recent trial by the Intergroupe Francophone du Myelome (IFM) compared early versus delayed ASCT in patients treated with VRd followed by lenalidomide maintenance.⁴³ Patients were randomized to receive either VRd (3 cycles) followed by ASCT and then VRd consolidation (2 cycles) versus VRd × 8 cycles with ASCT reserved for relapse. Both arms received lenalidomide maintenance for 1 year. A significant improvement in PFS was seen as expected with early ASCT, but this has so far not translated into a difference in OS (Table 7). At 8 years, the OS rate was 60% in the delayed ASCT groups and 62% in the early ASCT group.⁴⁵ Based on these results, it is reasonable to consider a delayed ASCT in patients with standard-risk multiple myeloma who prefer such an approach for personal and logistic reasons.

The role of tandem (double) ASCT is unclear. In earlier randomized trials, an improvement in OS was seen in two studies,^{120,121} but other studies failed to show such an improvement.^{122,123} More recent data are available from two other randomized trials, which are also inconclusive. In a trial conducted in Europe, an improvement in PFS and OS was seen with tandem ASCT in both standard- and high-risk patients.¹²⁴ However, no survival benefit has been seen so far in a randomized trial conducted in the United States by the Bone Marrow Transplantation Clinical Trials Network (BMT-CTN) in standard- or high-risk multiple myeloma (BMT-CTN 0702 trial).¹²⁵ The US trial more likely reflects the impact of tandem ASCT in the context of modern therapy when most new options for salvage are available. Selected patients with high-risk disease who are not in CR after the first transplant can be considered for a tandem ASCT. But routine tandem ASCT is not recommended outside of a clinical trial setting.

5.3.2 | Post-transplant consolidation

Consolidation therapy is a term used for the administration of a short course of therapy, usually with two or more drugs, prior to the start of long-term maintenance. The BMT-CTN 0702 trial had an arm that investigated the benefit of post-transplant consolidation therapy followed by lenalidomide maintenance versus lenalidomide maintenance alone.¹²⁵ In this trial, additional cycles of VRd chemotherapy

administered as consolidation after ASCT did not result in significant benefit. Unlike earlier trials, the BMT-CTN 0702 trial specifically isolated the effect of consolidation and is therefore more compelling than trials where one could not ascertain the precise added value of consolidation therapy on PFS and OS. Consolidation therapy after ASCT is not recommended, and patients should proceed to standard low-intensity maintenance therapy.

5.3.3 | Allogeneic transplantation

The role of allogeneic and non-myeloablative-allogeneic transplantation in multiple myeloma is controversial, with studies showing conflicting results.^{126,127} The treatment-related mortality (TRM) rate (10%–20%) and GVHD rates are fairly high.¹²⁸ Although allogeneic transplantation should still be considered as investigational, it may be a consideration for young patients with high-risk disease who are willing to accept a high TRM and the unproven nature of this therapy for a chance at better long-term survival.

Recommendations:

- ASCT should be considered in all eligible patients. But in standard-risk patients responding well to therapy, ASCT can be delayed until first relapse, provided stem cells are harvested early in the disease course.
- Except in selected patients with high-risk myeloma, tandem ASCT is not recommended outside of clinical trials.
- Allogeneic transplantation as frontline therapy should be considered investigational.

5.4 | Maintenance therapy

Maintenance therapy is indicated following ASCT. Maintenance therapy should also be considered after completing 8–12 cycles of initial therapy in patients treated without ASCT. Lenalidomide is the standard of care for maintenance therapy for most patients.^{129–134} In a meta-analysis of randomized trials, a significant improvement in PFS and OS was seen with lenalidomide maintenance compared with placebo or no therapy.¹³⁵ Lenalidomide maintenance is associated with a two-fold to three-fold increase in the risk of second cancers, and patients must be counseled in this regard and monitored.

The impact of lenalidomide maintenance in patients with high-risk multiple myeloma is unclear. In a meta-analysis, no significant OS benefit was seen in these subsets of high-risk patients.¹³⁵ However, in a more recent trial that was not part of the meta-analysis, benefit was seen in high-risk patients.¹³⁶ Bortezomib administered every other week has been shown to improve OS, particularly in patients with del(17p).¹³² Maintenance with bortezomib plus lenalidomide is recommended for patients with high-risk myeloma.¹³⁷ In patients unable to access or tolerate bortezomib, ixazomib is a reasonable alternative that has shown benefit in a placebo-controlled randomized trial.¹³⁸

Among patients who did not undergo upfront ASCT, based on the results of the SWOG trial, maintenance therapy with lenalidomide should be considered in patients who are in good performance status after completion of initial 8–12 cycles of triplet therapy.

Although the benefit of maintenance is now established, data on optimal duration are lacking. The role of daratumumab in patients who received it as part of frontline therapy is unclear.¹³⁹ We also need to consider the cost, toxicity, and inconvenience of long-term indefinite maintenance therapy. Many patients seek a drug-free interval. An ECOG trial is comparing lenalidomide maintenance given until progression versus a limited duration of 2 years (NCT03941860). Trials are also examining if the duration of maintenance can be modified based on MRD results.

Recommendations:

- I recommend lenalidomide maintenance for standard-risk patients following ASCT. I also recommend lenalidomide maintenance after 8–12 cycles of VRd among standard-risk patients who did not receive ASCT as part of initial therapy.
- I recommend maintenance with bortezomib plus lenalidomide for patients with high-risk multiple myeloma

6 | TREATMENT OF RELAPSED MULTIPLE MYELOMA

Almost all patients with multiple myeloma eventually relapse. The remission duration in relapsed multiple myeloma decreases with each regimen.¹⁴⁰ The median PFS and OS in patients with relapsed multiple myeloma refractory to lenalidomide and bortezomib is poor, with median times of 5 and 9 months, respectively.¹⁴¹ The choice of a treatment regimen at relapse is complicated and is affected by many factors including the timing of the relapse, response to prior therapy, aggressiveness of the relapse, and performance status (TRAP). Patients who are eligible for an ASCT should be considered for the procedure if they have never had one before, or if they have had an excellent remission duration, with the first ASCT defined as a remission of at least 36 months or longer with maintenance. In terms of drug therapy, a triplet regimen containing at least two new drugs that the patient is not refractory to should be considered.¹⁴²

An approach to the treatment of relapsed multiple myeloma is given in Figure 2. Major regimens used in the treatment of multiple myeloma, including relapsed disease, are listed in Table 6. Recent advances in the treatment of relapsed multiple myeloma, including new active agents and results of major randomized trials, are discussed below (Table 8).^{65,67,68,70,71,73,74,82,143–145} One important consideration is that the lenalidomide-containing regimens listed in Table 8 were tested mainly in patient populations who were not previously exposed to lenalidomide. In contrast, current clinical practice typically consists of patients who have been treated with lenalidomide and are often relapsing while on a lenalidomide-containing regimen. In patients who are considered refractory to

lenalidomide, one option is to consider pomalidomide-based regimens.

6.1 | Bortezomib-based regimens

These regimens are appropriate for patients who received a bortezomib-based triplet for a period of time, and then stopped therapy. In these patients if relapse occurs after a reasonable period of remission from all therapy, then restarting the same (or similar) bortezomib-based triplet is reasonable and also carries lower cost and risk. As in newly diagnosed multiple myeloma, VRd, VCd, and VTd are active regimens in relapsed disease.^{146,147}

6.2 | Daratumumab

Daratumumab is active in relapsed, refractory multiple myeloma.⁸³ In a phase II trial, daratumumab as a single-agent was produced a response rate of approximately 30% in heavily pretreated patients.⁸⁴ Based on these findings, daratumumab was first granted accelerated approval by the FDA in 2015 for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent, or who are double-refractory to a proteasome inhibitor and an immunomodulatory agent. Subsequently, several other daratumumab-based combinations have shown efficacy and have been approved by the FDA for relapsed disease. These include daratumumab, lenalidomide, dexamethasone (DRd), daratumumab, bortezomib, dexamethasone (DVd), daratumumab, pomalidomide, dexamethasone (DPd), and daratumumab, carfilzomib, dexamethasone (DKd) (Table 8). The various triplets available for use in relapsed disease have not been compared head-to-head, daratumumab-based regimens appear to have the greatest reduction in risk of progression, and may be preferred for first relapse subject to availability and cost considerations.¹⁴⁸ Daratumumab has also been approved as a subcutaneous formulation and thereby adding more flexibility in terms of administration.¹⁴⁹

6.3 | Carfilzomib

Carfilzomib is a novel keto-epoxide tetrapeptide proteasome inhibitor initially approved in 2013 for the treatment of relapsed refractory multiple myeloma in patients who have been previously treated with lenalidomide and bortezomib. The KRd regimen has been shown to be effective in a randomized trial, and is a major option for the treatment of relapsed disease (Table 8).⁶⁵ In another randomized trial, carfilzomib plus dexamethasone was associated with an improvement in PFS and OS compared with bortezomib plus dexamethasone in relapsed multiple myeloma.^{150,151} However, the dose of carfilzomib used in this trial (56 mg/m²) is twice the standard dose, and carries a much higher cost compared with bortezomib. Carfilzomib is typically administered twice-weekly at a dose of 27 mg/m² (refer to Table 6),

but a once-weekly schedule of 56–70 mg/m² may be equally effective and safe, and more convenient.¹⁵² Carfilzomib carries a lower risk of neurotoxicity than bortezomib, but a small proportion (5%) of patients can experience serious cardiac side effects. Carfilzomib-based regimens are important options at relapse, and can work well even in patients who are refractory to a bortezomib-containing regimen.

6.4 | Pomalidomide

Pomalidomide is an analog of lenalidomide and thalidomide initially approved in 2013 for the treatment of relapsed refractory multiple myeloma. It has significant activity in relapsed refractory multiple myeloma, even in patients failing lenalidomide.^{153,154} Response rate with pomalidomide plus dexamethasone (Pd) in patients refractory to lenalidomide and bortezomib is approximately 30%.^{155,156} In a randomized trial, Pd was found superior to high-dose dexamethasone in patients refractory to other forms of therapy for multiple myeloma (Table 8).¹⁵⁷ Pomalidomide-containing triplet regimens such as daratumumab, pomalidomide, dexamethasone (DPd) and carfilzomib, pomalidomide, dexamethasone (KPd) are important options at relapse for patients who are considered lenalidomide-refractory.^{69,158} In frail patients and in those with indolent relapse, the doublet regimen of Pd is a reasonable option.

6.5 | Elotuzumab

Elotuzumab is a monoclonal antibody targeting the signaling lymphocytic activation molecule F7 (SLAMF7).⁸² Unlike daratumumab, elotuzumab does not have single-agent activity but shows synergistic activity when combined with Rd (Table 8).⁸² Elotuzumab is well tolerated, and was initially approved in 2015 by the FDA to be given in combination with Rd for the treatment of patients with multiple myeloma who have received one to three prior therapies. However, elotuzumab may be more active in combination with pomalidomide than with lenalidomide. In a randomized trial conducted in patients refractory to lenalidomide and a proteasome inhibitor elotuzumab, pomalidomide, dexamethasone (EPd) was superior to Pd; median PFS 10.3 versus 4.7 months, $p = .008$. Based on this trial, EPd has been approved by the FDA for patients with myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor.

6.6 | Ixazomib

Ixazomib is an oral proteasome inhibitor that is active in both the relapsed refractory setting and in newly diagnosed multiple myeloma.^{71,159} It has the advantage of once-weekly oral administration. Compared with bortezomib, it has more gastrointestinal adverse events, but lower risk of neurotoxicity. In a randomized controlled trial in relapsed multiple myeloma, ixazomib, lenalidomide, dexamethasone (IRd) was found to improve PFS compared with Rd (Table 8).⁷¹ Based on these results, ixazomib was initially approved by the FDA in 2015

to be given in combination with Rd for the treatment of patients with multiple myeloma who have received at least one prior therapy.

6.7 | Selinexor


Selinexor blocks exportin 1 (XPO1) and leads to the accumulation and activation of various tumor suppressor proteins and the inhibition of nuclear factor kappaB. In one phase II trial, oral selinexor plus dexamethasone was found to have a response rate of 26% in patients refractory to at least one proteasome inhibitor, one immunomodulatory agent, and daratumumab.¹⁶⁰ Major side effects include thrombocytopenia, fatigue, nausea, and anorexia. Selinexor has been granted accelerated approval by the FDA for patients with relapsed refractory myeloma who have received at least four prior therapies, and whose disease is resistant to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. In a recent randomized trial, selinexor (given once a week) with bortezomib and dexamethasone (SVd) has shown improved response rates and PFS compared with bortezomib and dexamethasone (Vd) in patients with relapsed multiple myeloma.¹⁶¹

6.8 | Isatuximab

Isatuximab is a monoclonal antibody targeting CD38 that has shown promise in relapsed, refractory multiple myeloma. In a randomized trial, isatuximab, pomalidomide, dexamethasone (Isa-Pd) was associated with better PFS compared with Pd in patients with relapsed and refractory multiple myeloma; median PFS 11.5 months versus 6.5 months, $p = .001$.⁷³ Based on these data, isatuximab has been approved by the FDA for the treatment of relapsed refractory myeloma in patients who have received at least two previous lines of treatment including lenalidomide and a proteasome inhibitor. Isatuximab has shown comparable efficacy in combination with carfilzomib and dexamethasone (Isa-Kd) to what has been observed with DKd.⁷⁴ Overall, isatuximab is a reasonable alternative to daratumumab in myeloma, and the choice between the two monoclonal antibodies may be based on relative cost to a patient, access, and schedule.

6.9 | Doxorubicin and liposomal doxorubicin

Anthracyclines have marginal single-agent activity in multiple myeloma. A phase III randomized trial found that median time to progression (TTP) was superior with bortezomib plus pegylated liposomal doxorubicin compared with bortezomib alone, 9.3 months versus 6.5 months, respectively, $p < .001$.¹⁶² OS at 15 months was also superior, 76% compared with 65%, respectively, $p = .03$. Despite this study, liposomal doxorubicin is infrequently used in the treatment of relapsed multiple myeloma, given availability of other active agents. Doxorubicin-containing regimens such as PAD or VDT-PACE may be useful in the treatment of patients with aggressive multiple myeloma refractory to other standard myeloma agents.



*Consider salvage ASCT in patients eligible for ASCT who have not had transplant before; Consider 2nd auto SCT if eligible and had >36 months response duration with maintenance to first ASCT




FIGURE 2 Suggested options for the treatment of relapsed multiple myeloma in first relapse (A) and second or higher relapse (B). ASCT, autologous stem cell transplantation; DKd, daratumumab, carfilzomib, dexamethasone; DPd, daratumumab, pomalidomide, dexamethasone; DRd, daratumumab, lenalidomide, dexamethasone; EPd, Elotuzumab, pomalidomide, dexamethasone; ERd, Elotuzumab, lenalidomide, dexamethasone; IRd, ixazomib, lenalidomide, dexamethasone; Isa-Pd, isatuximab, carfilzomib, dexamethasone; Isa-Pd, isatuximab, pomalidomide, dexamethasone; KCd, carfilzomib, cyclophosphamide, dexamethasone; KPd, carfilzomib, pomalidomide; KRd, carfilzomib, lenalidomide, dexamethasone; VCD, bortezomib, cyclophosphamide, dexamethasone.

6.10 | Venetoclax

Venetoclax is not approved for use in multiple myeloma, but is commercially available, and has single-agent activity specifically in patients with t(11;14) subtype of multiple myeloma.¹⁶³ In a randomized trial, significantly higher mortality was seen with venetoclax in relapsed myeloma despite deeper responses and better PFS.¹⁶⁴ Therefore, venetoclax is best considered investigational, and its use should be restricted to patients with t(11;14) who have relapsed disease and limited options.

6.11 | Chimeric antigen receptor-T (CAR-T) cell therapy

CAR-T cell therapy is an exciting new immunotherapy option for patients with relapsed refractory myeloma.¹⁶⁵ Idecabtagene vicleucel (ide-cel; bb2121) and ciltacabtagene autoleucel (cilta-cel) are two separate CAR-T products targeting BCMA that have each shown significant clinical activity in phase II trials and have been granted accelerated approval by the FDA for the treatment of patients who

have failed four or more prior regimens. Among 128 patients with relapsed refractory myeloma treated on a phase II trial, ide-cel was associated with a response rate of 73%.¹⁶⁶ Thirty-three percent of patients had a CR or better. The median PFS was 8.8 months. Cytokine release syndrome was seen in 84%, and 5% were grade 3 or higher. Neurotoxicity was seen in 18%, and was grade 3 in 3%.

Ciltacabtagene autoleucel (cilta-cel) has also shown clinical activity in relapsed refractory multiple myeloma and provides an additional option for therapy. In a study of 97 patients with relapsed refractory multiple myeloma, the overall response rate was 97%, with 67% achieving stringent CR.¹⁶⁷ The 12-month PFS and OS were 77% and 89%, respectively. Cytokine release syndrome occurred in 95%, and were grade 3–4 in 4%. Neurotoxicity occurred in 21%, and were grade 3–4 severity in 9%.

6.12 | Belantamab mafodotin

Belantamab mafodotin is a humanized anti-BCMA antibody that is conjugated to monomethyl auristatin-F, a microtubule disrupting

TABLE 8 Results of recent phase III randomized studies in relapsed myeloma

Trial	Regimen	No. of patients	Overall response rate (%)	CR plus VGPR (%)	Progression-free survival (Median in months)	p value for progression-free survival	Overall survival ^a (Median in months)	p value for overall survival
Stewart et al. (ASPIRE) ^{65,143}	Rd	396	67	14	18	.0001	40	.04
	KRd	396	87	32	26		48	
Dimopoulos et al. (POLLUX) ⁶⁷	Rd	283	76	44	18.4	<.001	N/A; 87% at 1 year	NS
	DRd	286	93	76	NR		N/A; 92% at 1 year	
Palumbo et al. (CASTOR) ⁶⁸	Vd	247	63	29	7.2	<.001	N/A; 70% at 1 year	.30
	DVd	251	83	59	NR		N/A; 80% at 1 year	
Lonial et al. (ELOQUENT 2) ^{82,144}	Rd	325	66	28	15	<.001	40	N/A
	Elo-Rd	321	79	33	19		44	
Moreau et al. (TOURMALINE MM1) ⁷¹	Rd	362	72	7	15	.012	N/A	N/A
	IRd	360	78	12	21		N/A	
Dimopoulos et al. (APOLLO) ¹⁴⁵	Pd	153	46	20	7	.002	NR	N/A
	DPd	151	69	51	12		NR	
Attal et al. (ICARIA) ⁷³	Pd	153	35	9	6.5	<.001	NR; 63% at 1 year	.06
	Isa-Pd	154	60	32	11.5		NR; 72% at 1 year	
Dimopoulos et al. (CANDOR) ⁷⁰	Kd	154	75	49	16	.003	74% at 18 months	NS
	DKd	312	84	69	NR		80% at 18 months	
Moreau et al. (IKEMA) ⁷⁴	Kd	123	83	56	19	<.001	NR	NR
	Isa-Kd	179	87	73	NR		NR	

Abbreviations: CR, complete response; DKd, daratumumab, carfilzomib, dexamethasone; DPd, daratumumab, pomalidomide, dexamethasone; DRd, daratumumab, lenalidomide, dexamethasone; DVd, daratumumab, bortezomib, dexamethasone; Elo-Rd, elotuzumab, lenalidomide, dexamethasone; IRd, ixazomib, lenalidomide, dexamethasone; Isa-Kd, Isatuximab, carfilzomib, dexamethasone; Isa-Pd, isatuximab, pomalidomide, dexamethasone; Kd, carfilzomib, dexamethasone; KRd, carfilzomib, lenalidomide, dexamethasone; N/A, not available; NR, not reached; NS, not significant; Rd, lenalidomide plus dexamethasone; VGPR, very good partial response.

^aEstimated from updated publication when available; estimated from survival curves when not reported.

agent. In a phase II study conducted on 196 patients with relapsed or refractory multiple myeloma who had failed three or more lines of therapy, 33% responded to therapy.⁸⁶ The most common grade 3–4 toxicity was keratopathy in approximately 25% of patients. Unfortunately, the development of keratopathy results frequently in disruption of therapy after two doses limiting the efficacy and feasibility of this treatment.

6.13 | Other options

Despite the multiple options available, most patients eventually become refractory to all drug classes. Some additional options to consider for relapsed disease in refractory multiple myeloma

include the use of an alkylator-containing regimen such as VCd, or a quadruplet regimen in which a monoclonal antibody is added to a standard triplet regimen such as VRd or KRd. Other options include selinexor-containing regimens, bendamustine-containing regimens such as bendamustine, lenalidomide, dexamethasone or bendamustine, bortezomib, dexamethasone.^{168,169} For young high-risk patients with a suitable donor, allogeneic transplantation is an option as well.

6.14 | Emerging options

There are several investigational approaches that are promising, and patients should be considered for clinical trials investigating these

approaches. Of these, the most promising involves the use of bispecific antibodies.¹⁷⁰ Several bispecific antibodies targeting various antigens on the myeloma cell surface have been tested in clinical trials, and have shown promising single-agent activity.¹⁷¹ Bispecific antibodies have dual specificities to enable them to bind to both plasma cells and T cells. Most bispecifics (teclistamab, elranatamab, TNB-383B, AMG-701, REGN 5458) currently target the BCMA antigen on plasma cells and CD3 on T cells.¹⁷² There are however two that target different antigens on plasma cells, providing an important option for patients in whom a BCMA-targeted approach has already failed. Cevostamab is a bispecific antibody that targets Fc receptor-like protein 5 (FcRH5) expressed on plasma cells and CD3 on T cells. Talquetamab targets human G-protein coupled receptor family C group 5 member D (GPC5D) on plasma cells and CD3 on T cells.¹⁷³

Iberdomide, a cereblon E3 ligase modulator with antitumor and immunomodulatory properties, is another promising agent in clinical trials.¹⁷⁴ Iberdomide has shown single-agent activity in relapsed refractory myeloma with response rate of approximately 30%. Another promising drug in development is modakafusp alpha (TAK-573), a first-in-class immunocytokine that is designed to deliver interferon alpha-2b (IFN α 2b) to CD38 positive myeloma cells. It consists of two attenuated IFN α 2b molecules genetically fused to a humanized anti-CD38 monoclonal antibody.¹⁷⁵

Recommendations:

- Patients who are eligible for ASCT should consider ASCT as salvage therapy at first relapse if they have never had a transplant before, or if they have had a prolonged remission with the first ASCT.
- If relapse occurs more than 6 months after stopping therapy, the initial treatment regimen that successfully controlled the multiple myeloma initially can be re-instituted when possible.
- At first relapse, for patients who are not refractory to lenalidomide, my preferred option is DRd. If such patients are refractory to CD38 monoclonal antibody therapy, KRd is an alternative.
- At first relapse, for patients who are refractory to lenalidomide, my preferred option is DKd or Isa-Kd; alternatives are DPd or Isa-Pd. If such patients are refractory to CD38 monoclonal antibody therapy, carfilzomib, cyclophosphamide, dexamethasone (KCd) or KPd are alternatives.
- At second or higher relapse, I switch to a triplet regimen that contains at least two new drugs that the patient is not refractory to.
- Additional options to consider in patients with multiple relapses and disease that is refractory to conventional regimens include CAR-T cell or bispecific antibody therapy, alkylator-containing regimens such as VCd or KCd, intravenous melphalan, bendamustine-based regimens, multidrug chemotherapy regimens, allogeneic transplantation in young high-risk patients with a suitable donor, and venetoclax in patients with t(11;14) multiple myeloma.
- Patients with more aggressive relapse with plasma cell leukemia or extramedullary plasmacytomas often require therapy with a multidrug anthracycline-containing regimen such as VDT-PACE.

TABLE 9 Criteria for high-risk smoldering multiple myeloma^a

Mayo 2018 criteria
Any 2–3 of the following:
Serum M protein >2 gm/dL
Serum free light chain ratio (involved/uninvolved) >20
Bone marrow plasma cells >20%
Other high-risk factors
Progressive increase in M protein level (Evolving type of SMM) ^b
Bone marrow clonal plasma cells 50%–60%
t (4;14) or del 17p or 1q gain
Increased circulating plasma cells
MRI with diffuse abnormalities or with one focal lesion
PET-CT with focal lesion with increased uptake but without underlying osteolytic bone destruction

Abbreviations: M, monoclonal; MRI, magnetic resonance imaging; PET-CT, positron emission tomography-computed tomography; SMM, smoldering multiple myeloma.

^aNote that the term smoldering multiple myeloma excludes patients without end-organ damage who meet revised definition of multiple myeloma, namely clonal bone marrow plasma cells \geq 60% or serum free light chain (FLC) ratio \geq 100 (plus measurable involved FLC level \geq 100 mg/L), or more than one focal lesion on magnetic resonance imaging. The risk factors listed in this table variables associated with a higher risk of progression of SMM, and identify patients who need close follow up and consideration for clinical trials. Patients who are high risk by Mayo 2018 criteria are candidates for prophylactic therapy with lenalidomide or lenalidomide plus dexamethasone in the absence of clinical trials.

^bIncrease in serum monoclonal protein by \geq 25% on two successive evaluations within a 6-month period.

- The duration of therapy has not been well addressed in relapsed multiple myeloma, and in some regimens such as those employing parenteral proteasome inhibitors, it may be reasonable to stop therapy once a stable plateau has been reached in order to limit minimize risks of serious toxicity.

7 | SUPPORTIVE CARE

Zoledronic acid or pamidronate are recommended for all patients. A lower intensity schedule every 3–4 months may provide similar protection with less side effects compared with monthly administration.¹⁷⁶ Denosumab, a high-affinity monoclonal antibody targeting RANKL is an alternative, especially in patients with significant renal dysfunction.¹⁷⁷ When denosumab is discontinued for any reason, a dose of bisphosphonate should be considered in order to avoid rebound osteoclast activity.

The IMWG has recently provided guidelines for prevention and management of infections in myeloma.¹⁷⁸ Myeloma patients do not respond adequately to COVID vaccines and need boosters as recommended.¹⁷⁹ Prophylactic levofloxacin for the first 2–3 months of initial therapy should be considered to reduce the risk of serious infection. Prophylaxis with trimethoprim-sulfamethoxazole or an

alternative agent against pneumocystis jirovecii pneumonia should also be considered long term in all patients receiving long-term steroid or anti-CD38 monoclonal antibody therapy. Acyclovir or valacyclovir should be administered routinely for patients receiving proteasome inhibitors, anti-CD38 monoclonal antibodies, or elotuzumab as prophylaxis against herpes zoster. Intravenous immune globulin should be considered in hypogammaglobulinemic patients on daratumumab who develop frequent respiratory tract infections.

8 | SMOLDERING MULTIPLE MYELOMA

SMM is a stage that is clinically positioned between MGUS and multiple myeloma.¹⁸⁰ It comprises a heterogeneous group of patients, some of whom have multiple myeloma, which has not yet manifested with MDEs, and some who have premalignant MGUS. Patients with SMM have a risk of progression of approximately 10% per year for the first 5 years, 3% per year for the next 5 years, and 1% per year thereafter.²⁰ Patients with the highest risk of progression (ultra-high risk) have now been reclassified as having multiple myeloma by the new IMWG criteria.¹ Within the current definition of SMM (Table 1), there are two groups of patients: high risk (25% per year risk of progression in the first 2 years) and low risk (~5% per year risk of progression).¹⁸⁰ Risk factors for high-risk SMM are given in Table 9.^{181,182} The presence of 2 or 3 of these factors is associated with a median TTP to multiple myeloma of approximately 2 years, and is considered high-risk SMM (Mayo 2018 criteria).

Early studies in SMM failed to show an advantage to preventive intervention, but were limited by lack of power, safe and effective drugs, and a risk-adapted strategy.^{183,184} A randomized trial conducted in Spain found that patients with high-risk SMM had significant prolongation of PFS and OS with Rd compared with observation.^{91,185} A recent ECOG randomized trial provided additional confirmation and found that early therapy with lenalidomide prolonged time to end-organ damage in patients with high-risk SMM.⁹² Based on these two trials, patients with newly diagnosed high-risk SMM patients should be considered for early intervention with lenalidomide or lenalidomide plus dexamethasone.¹⁸⁶ An ongoing ECOG randomized trial is testing whether a standard myeloma therapeutic triplet (DRd) will be superior to prophylactic doublet therapy with lenalidomide plus dexamethasone. They are also candidates for clinical trials testing early intervention, some of which are testing intensive therapy with curative intent.¹⁸⁷

Recommendations:

- I recommend lenalidomide or lenalidomide plus dexamethasone for 2 years in patients with newly diagnosed high-risk SMM. All other patients should be observed without therapy.

AUTHOR CONTRIBUTIONS

S. Vincent Rajkumar conceived the paper, researched the literature, and wrote the manuscript.

ACKNOWLEDGMENTS

Supported in part by grants CA 168762 and CA186781 from the National Cancer Institute, Rockville, MD, USA, and the Marvin Family Grant.

CONFLICT OF INTEREST

The authors declare no conflicts of interest.

ORCID

S. Vincent Rajkumar  <https://orcid.org/0000-0002-5862-1833>

REFERENCES

1. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. *Lancet Oncol*. 2014;15:e538-e548.
2. Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. *Blood Cancer J*. 2020;10:94.
3. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. *CA Cancer J Clin*. 2021;71:7-33.
4. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton LJ 3rd. Incidence of multiple myeloma in Olmsted County, Minnesota: trend over 6 decades. *Cancer*. 2004;101:2667-2674.
5. Landgren O, Weiss BM. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis. *Leukemia*. 2009;23:1691-1697.
6. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1,027 patients with newly diagnosed multiple myeloma. *Mayo Clin Proc*. 2003;78:21-33.
7. Roodman GD. Pathogenesis of myeloma bone disease. *Leukemia*. 2009;23:435-441.
8. Hillengass J, Usmani S, Rajkumar SV, et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. *Lancet Oncol*. 2019;20:e302-e312.
9. Short KD, Rajkumar SV, Larson D, et al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. *Leukemia*. 2011;25:906-908.
10. Landgren O, Kyle RA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. *Blood*. 2009;113:5412-5417.
11. Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. *Blood*. 2009;113:5418-5422.
12. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. *N Engl J Med*. 2006;354:1362-1369.
13. Dispenzieri A, Katzmann JA, Kyle RA, et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. *Lancet*. 2010;375:1721-1728.
14. Murray D, Kumar SK, Kyle RA, et al. Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement. *Blood Cancer J*. 2019;9:102.
15. Landgren O, Graubard BI, Katzmann JA, et al. Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12 482 persons from the national health and nutritional examination survey. *Leukemia*. 2014;28:1537-1542.
16. Landgren O, Graubard BI, Kumar S, et al. Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance (MGUS) in 12,309 individuals 10 to 49 years old: a

- population-based study from the National Health and nutritional examination survey. *Blood Cancer J.* 2017;7:e618.
17. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis of monoclonal gammopathy of undetermined significance. *N Engl J Med.* 2002;346:564-569.
 18. Kyle RA, Larson DR, Therneau TM, et al. Long-term follow-up of monoclonal Gammopathy of undetermined significance. *N Engl J Med.* 2018;378:241-249.
 19. Therneau TM, Kyle RA, Melton LJ III, et al. Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition. *Mayo Clin Proc.* 2012;87:1071-1079.
 20. Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. *N Engl J Med.* 2007;356:2582-2590.
 21. Rajkumar SV, Gupta V, Fonseca R, et al. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. *Leukemia.* 2013;27:1738-1744.
 22. Neben K, Jauch A, Hielscher T, et al. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. *J Clin Oncol.* 2013;31:4325-4332.
 23. Lakshman A, Paul S, Rajkumar SV, et al. Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. *Leukemia.* 2018;32:1811-1815.
 24. Katzmann JA, Dispenzieri A, Kyle R, et al. Elimination of the need for urine studies in the screening algorithm for monoclonal Gammopathies by using serum Immunofixation and free light chain assays. *Mayo Clin Proc.* 2006;81:1575-1578.
 25. Chawla SS, Kumar SK, Dispenzieri A, et al. Clinical course and prognosis of non-secretory multiple myeloma. *Eur J Haematol.* 2014;95:57-64.
 26. Kumar SK, Mikhael JR, Buadi FK, et al. Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines. *Mayo Clin Proc.* 2009;84:1095-1110.
 27. Zhou Y, Barlogie B, Shaughnessy JD Jr. The molecular characterization and clinical management of multiple myeloma in the post-genome era. *Leukemia.* 2009;23:1941-1956.
 28. Dizdar O, Barista I, Kalyoncu U, et al. Biochemical markers of bone turnover in diagnosis of myeloma bone disease. *Am J Hematol.* 2007;82:185-191.
 29. Silvestris F, Lombardi L, De Matteo M, Bruno A, Dammacco F. Myeloma bone disease: pathogenetic mechanisms and clinical assessment. *Leuk Res.* 2007;31:129-138.
 30. Hillengass J, Mouloupoulos LA, Delorme S, et al. Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the international myeloma working group. *Blood Cancer J.* 2017;7:e599.
 31. Fernandez de Larrea C, Kyle R, Rosinol L, et al. Primary plasma cell leukemia: consensus definition by the international myeloma working group according to peripheral blood plasma cell percentage. *Blood Cancer J.* 2021;11:192.
 32. Dispenzieri A, Kyle R, Merlini G, et al. International myeloma working group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. *Leukemia.* 2009;23:215-224.
 33. Kumar S, Paiva B, Anderson KC, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. *Lancet Oncol.* 2016;17:e328-e346.
 34. Kumar S, Rajkumar SV. The multiple myelomas—current concepts in cytogenetic classification and therapy. *Nat Rev Clin Oncol.* 2018;15:409-421.
 35. Moreau P, Rajkumar SV. Multiple myeloma—translation of trial results into reality. *Lancet.* 2016;388:111-113.
 36. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. *Nat Rev Cancer.* 2002;2:175-187.
 37. Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. *Oncogene.* 2001;20:5611-5622.
 38. Fonseca R, Bailey RJ, Ahmann GJ, et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. *Blood.* 2002;100:1417-1424.
 39. Seidl S, Kaufmann H, Drach J. New insights into the pathophysiology of multiple myeloma. *Lancet Oncol.* 2003;4:557-564.
 40. Rajan AM, Rajkumar SV. Interpretation of cytogenetic results in multiple myeloma for clinical practice. *Blood Cancer J.* 2015;5:e365.
 41. Miller A, Asmann Y, Cattaneo L, et al. High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma. *Blood Cancer J.* 2017;7:e612.
 42. Durie BGM, Hoering A, Abidi MH, et al. Bortezomib, Lenalidomide and dexamethasone vs. Lenalidomide and dexamethasone induction followed by Lenalidomide and dexamethasone maintenance in patients with newly diagnosed myeloma without intent for immediate autologous stem cell transplant: results of the randomised phase III SWOG trial S0777. *Lancet.* 2017;389:519-527.
 43. Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, Bortezomib, and dexamethasone with transplantation for myeloma. *N Engl J Med.* 2017;376:1311-1320.
 44. Goldschmidt H, Lokhorst HM, Mai EK, et al. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial. *Leukemia.* 2018;32:383-390.
 45. Perrot A, Lauwers-Cances V, Cazaubiel T, et al. Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 trial. *Blood.* 2020;136:39.
 46. Facon T, Kumar SK, Plesner T, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. *Lancet Oncol.* 2021;22:1582-1596.
 47. Paquin A, Kumar SK, Buadi FK, et al. Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. *Blood.* 2017;130:3138.
 48. Russell SJ, Rajkumar SV. Multiple myeloma and the road to personalised medicine. *Lancet Oncol.* 2011;12:617-619.
 49. Vu T, Gonsalves W, Kumar S, et al. Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma. *Blood Cancer J.* 2015;5:e363.
 50. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. *Cancer.* 1975;36:842-854.
 51. Greipp PR, San Miguel JF, Durie BG, et al. International staging system for multiple myeloma. *J Clin Oncol.* 2005;23:3412-3420.
 52. Hari PN, Zhang MJ, Roy V, et al. Is the international staging system superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant. *Leukemia.* 2009;23:1528-1534.
 53. Kumar S, Fonseca R, Ketterling RP, et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. *Blood.* 2012;119:2100-2105.
 54. Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. *J Clin Oncol.* 2015;33:2863-2869.
 55. Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. *Leukemia.* 2014;28:1122-1128.
 56. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma [see comments]. *N Engl J Med.* 1999;341:1565-1571.

57. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.[see comment]. *N Engl J Med*. 2005;352:2487-2498.
58. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (rev/Dex) for newly diagnosed myeloma. *Blood*. 2005;106:4050-4053.
59. Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. *Blood*. 2006;108:3458-3464. doi:10.1182/blood-2006-04-015909
60. Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. *Lancet*. 2010;376:2075-2085.
61. Reeder CB, Reece DE, Kukreti V, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. *Leukemia*. 2009;23:1337-1341.
62. Kumar S, Flinn I, Richardson PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. *Blood*. 2012;119:4375-4382.
63. Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. *Blood*. 2010;116:679-686.
64. Bringhen S, Petrucci MT, Larocca A, et al. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. *Blood*. 2014;124:63-69.
65. Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. *N Engl J Med*. 2015;372:142-152.
66. Shah JJ, Stadtmauer EA, Abonour R, et al. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. *Blood*. 2015;126:2284-2290.
67. Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. *N Engl J Med*. 2016;375:1319-1331.
68. Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. *N Engl J Med*. 2016;375:754-766.
69. Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. *Blood*. 2017;130:974-981.
70. Dimopoulos M, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. *Lancet*. 2020;396:186-197.
71. Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, Lenalidomide, and dexamethasone for multiple myeloma. *N Engl J Med*. 2016;374:1621-1634.
72. Dimopoulos MA, Dytfield D, Grosicki S, et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. *N Engl J Med*. 2018;379:1811-1822.
73. Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. *Lancet*. 2019;394:2096-2107.
74. Moreau P, Dimopoulos MA, Mikhael J, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. *Lancet*. 2021;397:2361-2371.
75. Ito T, Ando H, Suzuki T, et al. Identification of a primary target of thalidomide teratogenicity. *Science*. 2010;327:1345-1350.
76. Krönke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. *Science*. 2014;343:301-305.
77. Lu G, Middleton RE, Sun H, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. *Science*. 2014;343:305-309.
78. Parman T, Wiley MJ, Wells PG. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity [see comments]. *Nat Med*. 1999;5:582-585.
79. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. *J Clin Oncol*. 2004;23:630-639.
80. Kumar S, Rajkumar SV. Many facets of bortezomib resistance/susceptibility. *Blood*. 2008;112:2177-2178.
81. Gutman D, Morales AA, Boise LH. Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma. *Leukemia*. 2009;23:2181-2183.
82. Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. *N Engl J Med*. 2015;373:621-631.
83. Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with Daratumumab monotherapy in multiple myeloma. *N Engl J Med*. 2015;373:1207-1219.
84. Lonial S, Weiss BM, Usmani SZ, et al. Single-agent daratumumab in heavily pre-treated patients with multiple myeloma: an open-label, international, multicentre phase 2 trial (Sirius). *Lancet*. 2016;387:1551-1560. doi:10.1016/S0140-6736(15)01120-4
85. Martin T, Baz R, Benson DM, et al. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. *Blood*. 2017;129:3294-3303.
86. Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. *Lancet Oncol*. 2020;21:207-221.
87. Facon T, Kumar S, Plesner T, et al. Daratumumab plus Lenalidomide and dexamethasone for untreated myeloma. *N Engl J Med*. 2019;380:2104-2115.
88. Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. *Lancet*. 2019;394:29-38.
89. Facon T, Verner CP, Bahlis NJ, et al. Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. *Blood*. 2021;137:3616-3628.
90. Kumar SK, Jacobus SJ, Cohen AD, et al. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. *Lancet Oncol*. 2020;21:1317-1330.
91. Mateos M-V, Hernández M-T, Giraldo P, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. *N Engl J Med*. 2013;369:438-447.
92. Lonial S, Jacobus SJ, Weiss M, et al. E3A06: randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma. *J Clin Oncol*. 2019;37:8001.
93. Rajkumar SV. Treatment of myeloma: cure vs control. *Mayo Clin Proc*. 2008;83:1142-1145.
94. Rajkumar SV, Gahrton G, Bergsagel PL. Approach to the treatment of multiple myeloma: a clash of philosophies. *Blood*. 2011;118:3205-3211.
95. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose

- dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. *Lancet Oncol.* 2010; 11:29-37.
96. Kumar S, Dispenzieri A, Lacy MQ, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. *Leukemia.* 2007;21:2035-2042.
 97. Palumbo A, Cavo M, Bringhen S, et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. *J Clin Oncol.* 2011;29:986-993.
 98. Larocca A, Cavallo F, Bringhen S, et al. Aspirin or enoxaparin thromboprophylaxis for newly-diagnosed multiple myeloma patients treated with lenalidomide. *Blood.* 2011;119:933-939.
 99. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. *Leukemia.* 2008;22:414-423.
 100. Moreau P, Hulin C, Macro M, et al. VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. *Blood.* 2016;127:2569-2574.
 101. Mateos MV, Oriol A, Martinez-Lopez J. Bortezomib/melphalan/prednisone (VMP) versus Bortezomib/thalidomide/prednisone (VTP) as induction therapy followed by maintenance treatment with Bortezomib/thalidomide (VT) versus Bortezomib/prednisone (VP): a randomised trial in elderly untreated patients with multiple myeloma older than 65 years. *Lancet Oncol.* 2010;11:934-941.
 102. Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. *J Clin Oncol.* 2010;28:5101-5109.
 103. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. *Lancet Oncol.* 2011;12:431-440.
 104. Moreau P, Hulin C, Marit G, et al. Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-01 trial. *Leukemia.* 2010;24:1233-1235.
 105. Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. *Blood.* 2012;120:1801-1809.
 106. Zingone A, Kwok ML, Manasanch EE, et al. Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide extended dosing (CRD-R) induces high rates of MRD negativity in newly diagnosed multiple myeloma (MM) patients. *Blood.* 2013;122:538.
 107. Voorhees PM, Kaufman JL, Laubach JP, et al. Depth of response to daratumumab (DARA), lenalidomide, bortezomib, and dexamethasone (RVd) improves over time in patients (pts) with transplant-eligible newly diagnosed multiple myeloma (NDMM): Griffin study update. *Blood.* 2019;134:691.
 108. Barlogie B, Anaissie E, van Rhee F, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. *Br J Haematol.* 2007;138:176-185.
 109. van Rhee F, Szymonifka J, Anaissie E, et al. Total therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide and dexamethasone, relevant to all phases of therapy. *Blood.* 2010;116:1220-1227.
 110. Kapoor P, Rajkumar SV. MAIA under the microscope - bringing trial design into focus. *Nat Rev Clin Oncol.* 2019;16:339-340.
 111. Magarotto V, Bringhen S, Offidani M, et al. A randomized phase 3 trial of melphalan-lenalidomide-prednisone (MPR) or cyclophosphamide-prednisone-lenalidomide (CPR) vs lenalidomide plus dexamethasone (Rd) in elderly newly diagnosed multiple myeloma patients. *Blood.* 2013;122:536.
 112. Mateos MV, Cavo M, Blade J, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. *Lancet.* 2020;395:132-141.
 113. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. *N Engl J Med.* 1996;335:91-97.
 114. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. *N Engl J Med.* 2003;348:1875-1883.
 115. Blade J, Vesole DH, Gertz M. Transplantation for multiple myeloma: who, when, how often? *Blood.* 2003;102:3469-3477.
 116. Kumar A, Loughran T, Alsina M, Durie BG, Djulbegovic B. Management of multiple myeloma: a systematic review and critical appraisal of published studies. *Lancet Oncol.* 2003;4:293-304.
 117. Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. *Blood.* 1998;92:3131-3136.
 118. Facon T, Mary JY, Harousseau JL, et al. Front-line or rescue autologous bone marrow transplantation (ABMT) following a first course of high dose melphalan (HDM) in multiple myeloma (MM). Preliminary results of a prospective randomized trial (CIAM) protocol. *Blood.* 1996;88(Suppl1):685a.
 119. Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US intergroup trial S9321. *J Clin Oncol.* 2006;24:929-936.
 120. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. *N Engl J Med.* 2003;349:2495-2502.
 121. Cavo M, Tosi P, Zamagni E, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. *J Clin Oncol.* 2007; 25:2434-2441.
 122. Fermand JP, Alberti C, Marolleau JP. Single versus tandem high dose therapy (HDT) supported with autologous blood stem cell (ABSC) transplantation using unselected or CD34-enriched ABSC: results of a two by two designed randomized trial in 230 young patients with multiple myeloma (MM). *Hematol J.* 2003;4(Suppl 1):S59.
 123. Goldschmidt H. Single vs. tandem autologous transplantation in multiple myeloma: the GMMG experience. *Hematol J.* 2003;4(Suppl 1):S61.
 124. Cavo M, Gay FM, Patriarca F, et al. Double autologous stem cell transplantation significantly prolongs progression-free survival and overall survival in comparison with single autotransplantation in newly diagnosed multiple myeloma: an analysis of phase 3 EMN02/HO95 study. *Blood.* 2017;130:401.
 125. Stadtmauer EA, Pasquini MC, Blackwell B, et al. Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 trial. *J Clin Oncol.* 2019;37: 589-597.
 126. Krishnan A, Pasquini MC, Logan B, et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. *Lancet Oncol.* 2011;12:1195-1203.
 127. Bruno B, Rotta M, Patriarca F, et al. A comparison of Allografting with autografting for newly diagnosed myeloma. *N Engl J Med.* 2007;356:1110-1120. doi:10.1056/NEJMoa065464
 128. Stewart AK. Reduced-intensity allogeneic transplantation for myeloma: reality bites. *Blood.* 2009;113:3135-3136.

129. Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. *N Engl J Med.* 2012;366:1782-1791.
130. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. *N Engl J Med.* 2012;366:1770-1781.
131. Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. *N Engl J Med.* 2014;371:895-905.
132. Sonneveld P, Schmidt-Wolf IGH, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. *J Clin Oncol.* 2012;30:2946-2955.
133. Palumbo A, Hajek R, Delforge M, et al. Continuous Lenalidomide treatment for newly diagnosed multiple myeloma. *N Engl J Med.* 2012;366:1759-1769.
134. Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. *N Engl J Med.* 2014;371:906-917.
135. Attal M, Palumbo A, Holstein SA, et al. Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): a meta-analysis (MA) of overall survival (OS). *J Clin Oncol.* 2016;34(suppl):A8001 (abstract).
136. Jackson GH, Davies FE, Pawlyn C, et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (myeloma XI): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol.* 2019;20:57-73.
137. Nooka AK, Kaufman JL, Muppidi S, et al. Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. *Leukemia.* 2014;28:690-693.
138. Dimopoulos MA, Gay F, Schjesvold F, et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. *Lancet.* 2019;393:253-264.
139. Moreau P, Hulin C, Perrot A, et al. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. *Lancet Oncol.* 2021;22:1378-1390.
140. Kumar SK, Therneau TM, Gertz MA, et al. Clinical course of patients with relapsed multiple myeloma. *Mayo Clin Proc.* 2004;79:867-874.
141. Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. *Leukemia.* 2012;26:149-157.
142. Moreau P, Kumar SK, San Miguel J, et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the international myeloma working group. *Lancet Oncol.* 2021;22:e105-e118.
143. Siegel DS, Dimopoulos MA, Ludwig H, et al. Improvement in overall survival with carfilzomib, Lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. *J Clin Oncol.* 2018;36:728-734.
144. Dimopoulos MA, Lonial S, White D, et al. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. *Br J Haematol.* 2017;178:896-905.
145. Dimopoulos MA, Terpos E, Boccadoro M, et al. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. *Lancet Oncol.* 2021;22:801-812.
146. Pineda-Roman M, Zangari M, van Rhee F, et al. VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. *Leukemia.* 2008;22:1419-1427.
147. Richardson PG, Weller E, Jagannath S, et al. Multicenter, phase I, dose-escalation trial of Lenalidomide plus Bortezomib for relapsed and relapsed/refractory multiple myeloma. *J Clin Oncol.* 2009;27:5713-5719.
148. Rajkumar SV, Kyle RA. Progress in myeloma - a monoclonal breakthrough. *N Engl J Med.* 2016;375:1390-1392.
149. Mateos MV, Nahi H, Legiec W, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. *Lancet Haematol.* 2020;7:e370-e380.
150. Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. *Lancet Oncol.* 2016;17:27-38.
151. Dimopoulos MA, Goldschmidt H, Niesvizky R, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. *Lancet Oncol.* 2017;18:1327-1337.
152. Bringhen S, Mina R, Petrucci MT, et al. Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies. *Haematologica.* 2019;104:1640-1647.
153. Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. *J Clin Oncol.* 2009;27:5008-5014.
154. Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). *Leukemia.* 2010;24:1934-1939.
155. Lacy MQ, Allred JB, Gertz MA, et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. *Blood.* 2011;118:2970-2975.
156. Richardson PG, Siegel DS, Vij R, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. *Blood.* 2014;123:1826-1832.
157. San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. *Lancet Oncol.* 2013;14:1055-1066.
158. Bringhen S, Mina R, Cafo AM, et al. Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study. *Leukemia.* 2018;32:1803-1807.
159. Kumar SK, Berdeja JG, Niesvizky R, et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. *Lancet Oncol.* 2014;15:1503-1512.
160. Chari A, Vogl DT, Gavriatopoulou M, et al. Oral Selinexor-dexamethasone for triple-class refractory multiple myeloma. *N Engl J Med.* 2019;381:727-738.
161. Grosicki S, Simonova M, Spicka I, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. *Lancet.* 2020;396:1563-1573.
162. Orłowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of Pegylated liposomal doxorubicin plus Bortezomib compared with Bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. *J Clin Oncol.* 2007;25:3892-3901.

163. Kumar S, Kaufman JL, Gasparetto C, et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. *Blood*. 2017;130:2401-2409.
164. Kumar S, Rajkumar SV. Surrogate endpoints in randomised controlled trials: a reality check. *Lancet*. 2019;394:281-283.
165. Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. *N Engl J Med*. 2019;380:1726-1737.
166. Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene Vicleucel in relapsed and refractory multiple myeloma. *N Engl J Med*. 2021;384:705-716.
167. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. *Lancet*. 2021;398:314-324.
168. Mey UJ, Brugger W, Schwarb H, et al. Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2(nd) -line therapy for relapsed and refractory multiple myeloma - a phase II trial. *Br J Haematol*. 2017;176:770-782.
169. Rodon P, Hulin C, Pegourie B, et al. Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe francophone du Myelome 2009-01 trial. *Haematologica*. 2015;100:e56-e59.
170. Kumar S, Rajkumar SV. BiTEing the tumor. *J Clin Oncol*. 2020;38:2077-2079.
171. Lakshman A, Kumar SK. Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: an update. *Am J Hematol*. 2021;97:99-118.
172. Usmani SZ, Garfall AL, van de Donk N, et al. Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. *Lancet*. 2021;398:665-674.
173. Verkleij CPM, Broekmans MEC, van Duin M, et al. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. *Blood Adv*. 2021;5:2196-2215.
174. Bjorklund CC, Kang J, Amatangelo M, et al. Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN. *Leukemia*. 2020;34:1197-1201.
175. Vogl DT, Kaufman JL, Holstein SA, et al. TAK-573, an anti-CD38/attenuated lfn alpha fusion protein, has clinical activity and modulates the lfn alpha receptor (IFNAR) pathway in patients with relapsed/refractory multiple myeloma. *Blood*. 2020;136:37-38.
176. Himmelstein AL, Foster JC, Khatcheressian JL, et al. Effect of longer-interval vs standard dosing of Zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. *JAMA*. 2017;317:48-58.
177. Nea R. An international, randomized, double blind trial comparing Denosumab with Zoledronic acid (ZA) for the treatment of bone disease in patients (pts) with newly diagnosed multiple myeloma. 16th International Myeloma Workshop (IMW); March 1-4, 2017; New Delhi, India, Abstracts 546 2017, e28.
178. Raje NS, Anaissie E, Kumar SK, et al. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the international myeloma working group. *Lancet Haematol*. 2022;9:e143-e161.
179. Terpos E, Rajkumar SV, Leung N. Neutralizing antibody testing in patients with multiple myeloma following COVID-19 vaccination. *JAMA Oncol*. 2022;8:201-202.
180. Rajkumar SV, Landgren O, Mateos MV. Smoldering multiple myeloma. *Blood*. 2015;125:3069-3075.
181. Lakshman A, Rajkumar SV, Buadi FK, et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. *Blood Cancer J*. 2018;8:59.
182. Mateos MV, Kumar S, Dimopoulos MA, et al. International myeloma working group risk stratification model for smoldering multiple myeloma (SMM). *Blood Cancer J*. 2020;10:102.
183. Hjorth M, Hellquist L, Holmberg E, Magnusson B, Rodger S, Westin J. Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I--a randomized study. Myeloma Group of Western Sweden. *Eur J Haematol*. 1993;50:95-102.
184. Grignani G, Gobbi PG, Formisano R, et al. A prognostic index for multiple myeloma. *Br J Cancer*. 1996;73:1101-1107.
185. Mateos MV, Hernandez MT, Giraldo P, et al. Lenalidomide plus dexamethasone versus observation in patients with high-risk smoldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. *Lancet Oncol*. 2016;17:1127-1136.
186. Lonial S, Rajkumar SV, Mateos MV. Risk stratified management approaches for smoldering multiple myeloma: clinical research becomes clinical practice. *Lancet Haematol*. 2022;9:e162-e165.
187. Mateos M-V, Martinez Lopez J, Rodriguez-Otero P, et al. Curative strategy for high-risk smoldering myeloma (GEM-CESAR): carfilzomib, Lenalidomide and dexamethasone (KRd) as induction followed by HDT-ASCT, consolidation with Krd and maintenance with Rd. *Blood*. 2017;130:402.

How to cite this article: Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. *Am J Hematol*. 2022;1-22. doi:10.1002/ajh.26590